Teva’s growth story leans heavily on a few newer medicines while its next wave of products is concentrated in tough-to-prove areas, leaving little room for missteps if competition or payer pushback heats up. At the same time, faster adoption of look‑alike medicines could squeeze prices and blunt the impact of cost cuts, setting up a more cautious path than many investors expect.Read more
Teva looks less like a plain low-cost drug maker as it leans harder into a handful of branded treatments and a busy late-stage pipeline that could lift profits and cash generation. But that upside depends on key products keeping their momentum, new medicines clearing trials and approvals, and pricing rules not taking a bigger bite than expected.Read more
Teva looks to shift from a generic-drug workhorse into a steadier growth story by leaning on a handful of newer branded medicines and a faster rollout of similar-to-brand biologic drugs, helped by cost cuts and a streamlined operation. The big question is whether that plan can outrun pressure from tough competition, government price rules, and the company’s heavy debt load.Read more
No trending discussion available.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
